Literature DB >> 12597885

Expression of recombinant human GM2-activator protein in insect cells: purification and characterization by mass spectrometry.

Michaela Wendeler1, Thorsten Lemm, Judith Weisgerber, Joerg Hoernschemeyer, Oliver Bartelsen, Ute Schepers, Konrad Sandhoff.   

Abstract

The GM2-activator protein (GM2AP) is a small non-enzymatic cofactor assisting the enzyme beta-hexosaminidase A in the lysosomal degradation of ganglioside GM2. Mutations in the gene encoding this glycoprotein lead to a fatal neurological disorder, the AB variant of GM2-gangliosidoses. In this paper, we describe the overexpression of GM2AP in Sf21 cells using both the baculovirus expression vector system (BEVS) and a non-lytic, plasmid-based insect cell expression system (InsectSelect). For the BEVS, the cDNA encoding human GM2AP-preproprotein was cloned in the expression vector pAcMP3. The recombinant virus generated by cotransfection with linearized baculovirus DNA was used to infect Sf21 cells. For the non-lytic expression system, the cDNA of GM2AP was inserted into the vector pIZ/V5-His, which was used for the constitutive expression in stably transformed Sf21 cells. As it was shown by immunoblot analysis of the cell culture supernatant, in both expression systems the GM2AP precursor protein was efficiently secreted into the medium. Following expression in the BEVS, the GM2AP was purified by sequential chromatography on Ni-NTA-agarose and Con A-Sepharose, resulting in a yield of up to 9 mg purified protein from 1L of cell culture supernatant. Following expression in stably transformed insect cells, the secreted protein was first concentrated by cation-exchange and purified by metal-ion affinity chromatography, with a yield of 0.1 mg/L cell culture supernatant. The biological activity of the recombinant protein was demonstrated by its ability to stimulate the hexosaminidase A-catalyzed degradation of ganglioside GM2, and the homogeneity and glycosylation were assessed by ESI-TOF mass spectrometry. While the protein expression in the BEVS led to partly glycosylated and partly non-glycosylated protein, the stably transformed cells produced only glycosylated protein. In both expression systems, the glycosylation was found to be identical and corresponded to the structure (GlcNAc)(2)Fuc(Man)(3). Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12597885     DOI: 10.1016/s1046-5928(02)00599-5

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  9 in total

1.  Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.

Authors:  Julie A Peterson; Tamara N Nelson; Adam J Kanack; Richard H Aster
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

2.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

3.  Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity.

Authors:  Susi Anheuser; Bernadette Breiden; Günter Schwarzmann; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2015-07-14       Impact factor: 5.922

4.  Role of endosomal membrane lipids and NPC2 in cholesterol transfer and membrane fusion.

Authors:  Misbaudeen Abdul-Hammed; Bernadette Breiden; Matthew A Adebayo; Jonathan O Babalola; Günter Schwarzmann; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2010-02-23       Impact factor: 5.922

5.  Ligand extraction properties of the GM2 activator protein and its interactions with lipid vesicles.

Authors:  Yong Ran; Gail E Fanucci
Journal:  Biophys J       Date:  2009-07-08       Impact factor: 4.033

Review 6.  My journey into the world of sphingolipids and sphingolipidoses.

Authors:  Konrad Sandhoff
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

Review 7.  Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.

Authors:  Shunji Tomatsu; Kazuki Sawamoto; Carlos J Alméciga-Díaz; Tsutomu Shimada; Michael B Bober; Yasutsugu Chinen; Hiromasa Yabe; Adriana M Montaño; Roberto Giugliani; Francyne Kubaski; Eriko Yasuda; Alexander Rodríguez-López; Angela J Espejo-Mojica; Oscar F Sánchez; Robert W Mason; Luis A Barrera; William G Mackenzie; Tadao Orii
Journal:  Drug Des Devel Ther       Date:  2015-04-01       Impact factor: 4.162

8.  Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.

Authors:  Keisuke Kitakaze; Chikako Tasaki; Youichi Tajima; Takatsugu Hirokawa; Daisuke Tsuji; Hitoshi Sakuraba; Kohji Itoh
Journal:  Biochem Biophys Rep       Date:  2016-06-08

9.  Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.

Authors:  Ferdinand Ngale Njume; Stephen Mbigha Ghogomu; Robert Adamu Shey; Lea Olive Tchouate Gainkam; Philippe Poelvoorde; Perrine Humblet; Joseph Kamgno; Annie Robert; Leon Mutesa; Christophe Lelubre; Evelina Edelweiss; Arnaud Poterszman; Susi Anheuser; Luc Vanhamme; Jacob Souopgui
Journal:  PLoS Negl Trop Dis       Date:  2019-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.